Putative kappa opioid heteromers as targets for developing analgesics free of adverse effects

Morgan Le Naour, Mary M. Lunzer, Michael D. Powers, Alexander E. Kalyuzhny, Michael A. Benneyworth, Mark J. Thomas, Philip S. Portoghese

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

It is now generally recognized that upon activation by an agonist, β-arrestin associates with G protein-coupled receptors and acts as a scaffold in creating a diverse signaling network that could lead to adverse effects. As an approach to reducing side effects associated with κ opioid agonists, a series of β-naltrexamides 3-10 was synthesized in an effort to selectively target putative κ opioid heteromers without recruiting β-arrestin upon activation. The most potent derivative 3 (INTA) strongly activated KOR-DOR and KOR-MOR heteromers in HEK293 cells. In vivo studies revealed 3 to produce potent antinociception, which, when taken together with antagonism data, was consistent with the activation of both heteromers. 3 was devoid of tolerance, dependence, and showed no aversive effect in the conditioned place preference assay. As immunofluorescence studies indicated no recruitment of β-arrestin2 to membranes in coexpressed KOR-DOR cells, this study suggests that targeting of specific putative heteromers has the potential to identify leads for analgesics devoid of adverse effects.

Original languageEnglish (US)
Pages (from-to)6383-6392
Number of pages10
JournalJournal of Medicinal Chemistry
Volume57
Issue number15
DOIs
StatePublished - Aug 14 2014

Fingerprint

Arrestin
Opioid Analgesics
Analgesics
HEK293 Cells
G-Protein-Coupled Receptors
Fluorescent Antibody Technique
Membranes

Cite this

Putative kappa opioid heteromers as targets for developing analgesics free of adverse effects. / Le Naour, Morgan; Lunzer, Mary M.; Powers, Michael D.; Kalyuzhny, Alexander E.; Benneyworth, Michael A.; Thomas, Mark J.; Portoghese, Philip S.

In: Journal of Medicinal Chemistry, Vol. 57, No. 15, 14.08.2014, p. 6383-6392.

Research output: Contribution to journalArticle

Le Naour, Morgan ; Lunzer, Mary M. ; Powers, Michael D. ; Kalyuzhny, Alexander E. ; Benneyworth, Michael A. ; Thomas, Mark J. ; Portoghese, Philip S. / Putative kappa opioid heteromers as targets for developing analgesics free of adverse effects. In: Journal of Medicinal Chemistry. 2014 ; Vol. 57, No. 15. pp. 6383-6392.
@article{769442186f6a4cafb81597f201abe13c,
title = "Putative kappa opioid heteromers as targets for developing analgesics free of adverse effects",
abstract = "It is now generally recognized that upon activation by an agonist, β-arrestin associates with G protein-coupled receptors and acts as a scaffold in creating a diverse signaling network that could lead to adverse effects. As an approach to reducing side effects associated with κ opioid agonists, a series of β-naltrexamides 3-10 was synthesized in an effort to selectively target putative κ opioid heteromers without recruiting β-arrestin upon activation. The most potent derivative 3 (INTA) strongly activated KOR-DOR and KOR-MOR heteromers in HEK293 cells. In vivo studies revealed 3 to produce potent antinociception, which, when taken together with antagonism data, was consistent with the activation of both heteromers. 3 was devoid of tolerance, dependence, and showed no aversive effect in the conditioned place preference assay. As immunofluorescence studies indicated no recruitment of β-arrestin2 to membranes in coexpressed KOR-DOR cells, this study suggests that targeting of specific putative heteromers has the potential to identify leads for analgesics devoid of adverse effects.",
author = "{Le Naour}, Morgan and Lunzer, {Mary M.} and Powers, {Michael D.} and Kalyuzhny, {Alexander E.} and Benneyworth, {Michael A.} and Thomas, {Mark J.} and Portoghese, {Philip S.}",
year = "2014",
month = "8",
day = "14",
doi = "10.1021/jm500159d",
language = "English (US)",
volume = "57",
pages = "6383--6392",
journal = "Journal of Medicinal Chemistry",
issn = "0022-2623",
publisher = "American Chemical Society",
number = "15",

}

TY - JOUR

T1 - Putative kappa opioid heteromers as targets for developing analgesics free of adverse effects

AU - Le Naour, Morgan

AU - Lunzer, Mary M.

AU - Powers, Michael D.

AU - Kalyuzhny, Alexander E.

AU - Benneyworth, Michael A.

AU - Thomas, Mark J.

AU - Portoghese, Philip S.

PY - 2014/8/14

Y1 - 2014/8/14

N2 - It is now generally recognized that upon activation by an agonist, β-arrestin associates with G protein-coupled receptors and acts as a scaffold in creating a diverse signaling network that could lead to adverse effects. As an approach to reducing side effects associated with κ opioid agonists, a series of β-naltrexamides 3-10 was synthesized in an effort to selectively target putative κ opioid heteromers without recruiting β-arrestin upon activation. The most potent derivative 3 (INTA) strongly activated KOR-DOR and KOR-MOR heteromers in HEK293 cells. In vivo studies revealed 3 to produce potent antinociception, which, when taken together with antagonism data, was consistent with the activation of both heteromers. 3 was devoid of tolerance, dependence, and showed no aversive effect in the conditioned place preference assay. As immunofluorescence studies indicated no recruitment of β-arrestin2 to membranes in coexpressed KOR-DOR cells, this study suggests that targeting of specific putative heteromers has the potential to identify leads for analgesics devoid of adverse effects.

AB - It is now generally recognized that upon activation by an agonist, β-arrestin associates with G protein-coupled receptors and acts as a scaffold in creating a diverse signaling network that could lead to adverse effects. As an approach to reducing side effects associated with κ opioid agonists, a series of β-naltrexamides 3-10 was synthesized in an effort to selectively target putative κ opioid heteromers without recruiting β-arrestin upon activation. The most potent derivative 3 (INTA) strongly activated KOR-DOR and KOR-MOR heteromers in HEK293 cells. In vivo studies revealed 3 to produce potent antinociception, which, when taken together with antagonism data, was consistent with the activation of both heteromers. 3 was devoid of tolerance, dependence, and showed no aversive effect in the conditioned place preference assay. As immunofluorescence studies indicated no recruitment of β-arrestin2 to membranes in coexpressed KOR-DOR cells, this study suggests that targeting of specific putative heteromers has the potential to identify leads for analgesics devoid of adverse effects.

UR - http://www.scopus.com/inward/record.url?scp=84906094177&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84906094177&partnerID=8YFLogxK

U2 - 10.1021/jm500159d

DO - 10.1021/jm500159d

M3 - Article

C2 - 24978316

AN - SCOPUS:84906094177

VL - 57

SP - 6383

EP - 6392

JO - Journal of Medicinal Chemistry

JF - Journal of Medicinal Chemistry

SN - 0022-2623

IS - 15

ER -